This program is intended for hematologists/oncologists and other multidisciplinary care team members who treat patients with lymphomas.
This program aims to improve learners’ knowledge, confidence, and competence in integrating the latest clinical guidance and expert recommendations in the application of CAR T-cell therapy for the treatment of lymphomas into clinical practice.
Upon completion of this activity, participants should be able to:
Recall the scientific rationale, key evidence, and expanding role of current and emerging CAR T-cell therapies in CLL/SLL, DLBCL, FL, and MCL
Plan individualized therapeutic strategies to optimize integration of CAR T-cell therapies for patients with hematologic malignancies including patient selection, referral to specialized CAR T-cell treatment centers, patient care coordination, and pre/post treatment support
Implement proactive strategies for monitoring and managing toxicities associated with CAR T-cell therapies in patients with hematologic malignancies
Appraise ongoing clinical trials evaluating CAR T-cell therapy for the treatment of patients with hematologic malignancies for appropriate and inclusive patient enrollment
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Michael R. Bishop, MD
Professor of Medicine, Director
Section of Hematology/Oncology,
Cellular Therapy Program
University of Chicago
Michael R. Bishop, MD: consultant/advisor/speaker: CRISPR Therapeutics, Kite/Gilead, Novartis; researcher: Autolus.
Kathleen Dorritie, MD
Assistant Professor of Medicine
Division of Hematology/Oncology
UPMC Hillman Cancer Center,
University of Pittsburgh
Kathleen Dorritie, MD: consultant/advisor/speaker: Bristol Myers Squibb; researcher (paid to institution): Juno/Bristol Myers Squibb, Kite/Gilead, Genmab, Janssen.
Julie M. Vose, MD, MBA
Newmann M. and Milde E. Harris Professor
Department of Internal Medicine
University of Nebraska Medical Center
Julie M. Vose, MD, MBA: consultant/advisor/speaker: AbbVie, MEI Pharma; researcher: Epizyme, Kite, Loxo, Novartis.
The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.
Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from June 23, 2023, through June 22, 2024:
This program has been made available online.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.